Acute Bacterial Meningitis with Coincident Methamphetamine Use: A Case Report and Review of the Literature
Corresponding Author
Michael Heninger M.D.
Fulton County Medical Examiner's Office, 430 Pryor Street SW, Atlanta, GA 30312
Additional information and reprint requests:
Michael Heninger, M.D.
Fulton County Medical Examiner's Office
430 Pryor Street SW
Atlanta, GA 30312
E-mail: [email protected]
Search for more papers by this authorKim A. Collins M.D.
Fulton County Medical Examiner's Office, 430 Pryor Street SW, Atlanta, GA 30312
Search for more papers by this authorCorresponding Author
Michael Heninger M.D.
Fulton County Medical Examiner's Office, 430 Pryor Street SW, Atlanta, GA 30312
Additional information and reprint requests:
Michael Heninger, M.D.
Fulton County Medical Examiner's Office
430 Pryor Street SW
Atlanta, GA 30312
E-mail: [email protected]
Search for more papers by this authorKim A. Collins M.D.
Fulton County Medical Examiner's Office, 430 Pryor Street SW, Atlanta, GA 30312
Search for more papers by this authorAbstract
Methamphetamine is a synthetic stimulant that can adversely affect the central nervous system and the immune system. Through various mechanisms, methamphetamine is toxic to neurons, endothelial cells, lymphocytes, granulocytes, and macrophages resulting in systemic damage. Reported is the sudden demise of an otherwise healthy 31-year-old woman with a history of stimulant abuse. At autopsy, acute bacterial meningitis was identified. Microbiology cultures grew a single isolate of Streptococcus pneumoniae. Toxicology was positive for amphetamine (0.13 mg/L) and methamphetamine (0.8 mg/L). The cause of death was classified as acute bacterial meningitis with methamphetamine use. Either the acute bacterial meningitis or the methamphetamine toxicity would have been sufficient to result in death; however, the concurrent pathophysiology of the two entities must be understood. A review of the current literature assesses the mechanisms of injury attributed to acute and chronic methamphetamine use, bacterial meningitis, and the synergy between the two.
References
- 1Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006; 1: 223–36.
- 2Swartz MN. Bacterial meningitis—a view of the past 90 years. N Engl J Med 2004; 351: 1826–8.
- 3Fulton SA, Salatz RA. Infections of the nervous system. In: TE Andreoli, CJ Carpenter, RC Griggs, IJ Benjamin, editors. Andreoli and Carpenter's Cecil essentials of medicine, 7th edn. Philadelphia, PA: Elsevier, 2007; 910–4.
- 4van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med 2006; 354: 44–56.
- 5Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL. Bacterial meningitis in the United States in 1995. Active surveillance team. N Engl J Med 1997; 337: 970–6.
- 6Bloch KC. Chapter 4. Infectious diseases. In: SJ McPhee, GD Hammer, editors. Pathophysiology of disease, 6e, 2009. http://www.accessmedicine.com/content.aspx?aID=5366994 (assessed October 3, 2010).
- 7Kim KS. Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury. Nat Rev Neurosci 2003; 4: 376–85.
- 8Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med 1992; 327: 864–72.
- 9Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002; 2: 721–36.
- 10Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009; 104(7): 1085–99.
- 11Martins T, Baptista S, Goncalves J, Leal E, Milhazes N, Borges F, et al. Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res 2011; 1411: 28–40.
- 12Ramirez SH, Potula R, Fan S, Eidem T, Papugani A, Reichenbach N, et al. Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 2009; 29: 1933–45.
- 13Sharma HS, Sjoquist PO, Ali SF. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51. Curr Pharm Des 2007; 13: 1903–23.
- 14Yamamoto BK, Moszczynska A, Gudelsky GA. Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 2010; 1187: 101–21.
- 15Phelps G, Speaker HA, Sabol KE. Relationship between methamphetamine-induced behavioral activation and hyperthermia. Brain Res 2010; 1357: 41–52.
- 16Kiyatkin EA, Sharma HS. Acute methamphetamine intoxication, brain hyperthermia, blood-brain barrier, brain edema, and morphological cell abnormalities. Int Rev Neurobiol 2009; 88: 65–100.
- 17Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Stikker W Jr, et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 1994; 268: 1571–80.
- 18Bowyer JF, Ali S. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 2006; 60: 521–32.
- 19Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 2004; 311: 1–7.
- 20Sharma HS, Kiyatkin EA. Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: an experimental study using light and electron microscopy. J Chem Neuroanat 2009; 37: 18–32.
- 21Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 2007; 35: 1127–32.
- 22Goncalves J, Martins T, Ferreira R, Milhazes N, Borges F, Ribeiro CF, et al. Methamphetamine-induced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain. Ann N Y Acad Sci 2008; 1139: 103–11.
- 23Thomas DM, Kuhn DM. Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem 2005; 92: 790–7.
- 24Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 2008; 28: 5756–61.
- 25Potula R, Hawkins BJ, Cenna JM, Fan S, Dykstra H, Ramierez SH, et al. Methamphetamine causes mitochondrial oxidative damage in human T lymphocytes leading to functional impairment. J Immunol 2010; 185: 2867–76.
- 26In SW, Son EW, Rhee Dk, Pyo S. Methamphetamine administration produces immunomodulation in mice. J Toxicol Environ Health 2005; 68: 2133–45.
- 27Martinez LR, Mihu MR, Gacser A, Santambrogio L, Nosanchuk D. Methamphetamine enhances histoplasmosis by immunosuppression of the host. J Infect Dis 2009; 200: 131–41.
- 28Reiner BC, Keblesh JP, Xiong H. Methamphetamine abuse, HIV infection, and neurotoxicity. Int J Physiol Pathphysiol Pharmacol 2009; 1: 162–79.
- 29Cadet JL, Krasnova IN. Interactions of methamphetamine and HIV: cellular and molecular mechanisms of toxicity potentiation. Neurotox Res 2007; 112: 181–204.
10.1007/BF03033915 Google Scholar
- 30Huff B. Methamphetamine and HIV. Beta 2006; 18: 42–7.
- 31Cooper HL, Brady JE, Ciccarone D, Templaski B, Gostnell K, Friedman SR. Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. Clin Infect Dis 2007; 45: 1200–3.
- 32Phillips KT, Stein MD. Risk practices associated with bacterial infections among injection drug users in Denver, Colorado. Am J Drug Alcohol Abuse 2010; 36: 92–7.
- 33Chuck RS, Williams JM, Goldberg MA, Lubniewski AJ. Recurrent corneal ulcerations associated with smokeable methamphetamine abuse. Am J Ophthalmol 1996; 121: 571–2.
- 34Gotway MB, Marder SR, Hanks DK, Leung JW, Dawn SK, Gean AD, et al. Thoracic complications of illicit drug use: an organ system approach. Radiographics 2002; 22: S119–35.
- 35Marshal BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction 2010; 105: 991–1002.